Tanvex BioPharma, Inc. (TPE:6541)

Market Cap	10.62B -36.4%
Revenue (ttm)	400.97M +1,056.3%
Net Income	-1.50B
EPS	-6.13
Shares Out	264.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,427
Average Volume	430,244
Open	41.50
Previous Close	40.85
Day's Range	39.90 - 41.50
52-Week Range	39.90 - 68.00
Beta	0.20
RSI	39.33
Earnings Date	May 6, 2026

About Tanvex BioPharma

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2025, Tanvex BioPharma's revenue was 400.97 million, an increase of 1056.27% compared to the previous year's 34.68 million. Losses were -1.50 billion, 8.59% more than in 2024.